Tome Biosciences: Programmable Genomic Integration Company Raises Over $200 Million
By Amit Chowdhry ● Dec 18, 2023
Tome Biosciences - a programmable genomic integration company - recently announced it has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence of any size into any programmed genomic location. And the company has raised $213 million in Series A and B funding from investors: Andreessen Horowitz (a16z) Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments, and others.